CNBX Pharmaceuticals Inc. (CNBX)
OTCMKTS
· Delayed Price · Currency is USD
0.0002
-0.0001 (-33.33%)
Apr 29, 2026, 11:20 AM EST
CNBX Pharmaceuticals Employees
CNBX Pharmaceuticals had 1 employees as of February 28, 2026. The number of employees did not change since the number was reported on August 31, 2025.
Employees
1
Change
n/a
Growth
n/a
Revenue / Employee
n/a
Profits / Employee
-$367,653
Market Cap
245.15K
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| Altamira Therapeutics | 11 |
| Bio-Path Holdings | 1 |
| Eloxx Pharmaceuticals | 10 |
| Actavia Life Sciences | 1 |
| Emmaus Life Sciences | 33 |
| Hepion Pharmaceuticals | 2 |
CNBX Pharmaceuticals News
- 3 years ago - CNBX to Enter the Cancer Immunotherapy Market After Acquiring a Controlling Interest in TaGeza Biopharma - PRNewsWire
- 3 years ago - CNBX Files New PCT Patent Application For Cannabinoids-Based Neoadjuvant Cancer Therapy - PRNewsWire
- 3 years ago - CNBX Patent Application "Composition and Method for Treating Cancer with Cannabinoids" Enters National Phase in US and Israel - PRNewsWire
- 3 years ago - CNBX Peer-reviewed Study: "Possible Future Therapeutic Value" for CNBX Proprietary Drug Candidate - PRNewsWire
- 3 years ago - CNBX Pharmaceuticals Announces New Patent Granted in Australia - PRNewsWire
- 4 years ago - CNBX Pharmaceuticals Granted Patent in Hong Kong - PRNewsWire
- 4 years ago - Cannabics Pharmaceuticals Changes Name to CNBX Pharmaceuticals - PRNewsWire
- 4 years ago - CNBX Selects API Supplier Purisys to Support Planned IND Fillings and Phase I/II (a) Clinical Trials - PRNewsWire